CA2856037C — Modulators of atp-binding cassette transporters
Assigned to Vertex Pharmaceuticals Inc · Expires 2017-03-07 · 9y expired
What this patent protects
A compound of formula (I): (see formula I) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising a compound according to formula (I) and a pharmaceutically acceptable carrier, a kit for use in measuring the activity of an ABC transporter or a frag…
USPTO Abstract
A compound of formula (I): (see formula I) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising a compound according to formula (I) and a pharmaceutically acceptable carrier, a kit for use in measuring the activity of an ABC transporter or a fragment thereof in a biological sample in vitro or in vivo, comprising a composition comprising the compound of formula (I) and instructions for a) contacting the composition with the biological sample and b) measuring activity of said ABC transporter or a fragment thereof, and use of an effective amount of the compound of formula (I) or the pharmaceutically acceptable salt thereof for treating or lessening the severity of a disease in a patient need thereof.
Drugs covered by this patent
- Imbruvica (ibrutinib) · AbbVie
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.